AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33481771 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxyindole (5-HI) stimulation in a cell line model of intestinal enterochromaffin cells
Number of subjects: 0
Study 32544120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 32544120 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 35821447 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-control with biofeedback group (N = 12)
Number of subjects: 24
Study 35821447 — intervention group
Group type: COMPARATOR
Intervention: Motor-control group (N = 12)
Number of subjects: 24
Study 33092819 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with cisplatin/paclitaxel q21 followed by cold‐knife conization (CKC)
Number of subjects: 25
Study 33092819 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 34081314 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (reverse Trendelenburg position, dysphagia screening, oral care, vaccinations)
Number of subjects: 123
Study 34081314 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 123
Study 34081314 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study 32898006 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation (SAC) therapy
Number of subjects: 84
Study 32898006 — intervention group
Group type: COMPARATOR
Intervention: No systemic anticoagulation (historic cohort)
Number of subjects: 84
Study 616860962 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5mg of apo‐carvedilol
Number of subjects: 66
Study 616860962 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg of apo‐carvedilol
Number of subjects: 66
Study 616860962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35809772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (n = 30)
Number of subjects: 60
Study 35809772 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (n = 30)
Number of subjects: 60
Study 34363864 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly professional-mode flash glucose monitoring (sensor worn for 14 days; data discussed at clinic visit)
Number of subjects: 299
Study 34363864 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study 34363864 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly professional-mode flash glucose monitoring
Number of subjects: 299
Study 32445295 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive audio-tactile map
Number of subjects: 14
Study 32445295 — intervention group
Group type: COMPARATOR
Intervention: Verbally annotated tactile map (Control)
Number of subjects: 14
Study 35565177 — intervention group
Group type: EXPERIMENTAL
Intervention: New occupational health program implementation
Number of subjects: 32
Study 34517272 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0
Study 35478086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention for 30 days
Number of subjects: 623
Study 35478086 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention for 30 days
Number of subjects: 623
Study 35478086 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 623
Study 33506031 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Shockwave Therapy (F‐SWT)
Number of subjects: 46
Study 33506031 — intervention group
Group type: COMPARATOR
Intervention: Radial Shockwave Therapy (R‐SWT)
Number of subjects: 46
Study 34881965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone condition
Number of subjects: 57
Study 34881965 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper condition
Number of subjects: 57
Study 34881965 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study 32636360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 2
Study 32636360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 35581452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid arm (digital health intervention + CHW support)
Number of subjects: 150
Study 35581452 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm (wireless glucometer if needed)
Number of subjects: 150
Study 32894382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways (with a mutual gaze component)
Number of subjects: 78
Study 32894382 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual (SAU)
Number of subjects: 78
Study 32894382 — intervention group
Group type: COMPARATOR
Intervention: Communication
Number of subjects: 78
Study 32402558 — intervention group
Group type: EXPERIMENTAL
Intervention: SS with breast milk (SSB)
Number of subjects: 108
Study 32402558 — intervention group
Group type: EXPERIMENTAL
Intervention: SS with sensory stimulation (SSS)
Number of subjects: 108
Study 32402558 — intervention group
Group type: COMPARATOR
Intervention: Oral sucrose alone (S24%)
Number of subjects: 108
Study 32402558 — intervention group
Group type: EXPERIMENTAL
Intervention: SS with sucrose (SSS)
Number of subjects: 108
Study 34988638 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who chose to lie during the interview
Number of subjects: 0
Study 34988638 — intervention group
Group type: COMPARATOR
Intervention: Participants who chose to tell the truth during the interview
Number of subjects: 0
Study 33851349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 33
Study 33851349 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 33
Study 32328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy (LT) plus lymph node dissection (LND)
Number of subjects: 129
Study 32328782 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy (TT) plus lymph node dissection (LND)
Number of subjects: 129
Study 32328782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study 35701060 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal health package (MHP)
Number of subjects: 40
Study 35701060 — intervention group
Group type: COMPARATOR
Intervention: Standard care (observation)
Number of subjects: 40
Study 32526534 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care Plus (SCP)
Number of subjects: 1890
Study 32526534 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care/Stepped Care (CC/SC)
Number of subjects: 1890
Study 34307681 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercises plus Manual Therapy (PRE plus MT)
Number of subjects: 80
Study 34307681 — intervention group
Group type: COMPARATOR
Intervention: Motor Control Exercises (MCE)
Number of subjects: 80
Study 32121011 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond supplementation
Number of subjects: 5
Study 32121011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 35197068 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health education regarding HPV and HPV vaccines for seven days
Number of subjects: 946
Study 35197068 — intervention group
Group type: COMPARATOR
Intervention: Non-HPV-related materials (control group)
Number of subjects: 946
Study 33226075 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing subsidy (MTO voucher treatment)
Number of subjects: 2829
Study 33226075 — intervention group
Group type: EXPERIMENTAL
Intervention: Average post-random-assignment COI
Number of subjects: 2829
Study 32281249 — intervention group
Group type: EXPERIMENTAL
Intervention: Saugella Hydraserum (SIS)
Number of subjects: 40
Study 32281249 — intervention group
Group type: COMPARATOR
Intervention: Lactacyd Feminine Hygiene (LTC)
Number of subjects: 40
Study 34149690 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiated during primary HIV infection (PHI) for up to three years
Number of subjects: 66
Study 34149690 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-specific cells epigenetic profiling
Number of subjects: 66
Study 34149690 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected controls
Number of subjects: 66
Study 33123802 — intervention group
Group type: EXPERIMENTAL
Intervention: DNX HBr hemihydrate tablet formulations in fed state (high fat)
Number of subjects: 0
Study 33123802 — intervention group
Group type: EXPERIMENTAL
Intervention: DNX HBr monohydrate formulation
Number of subjects: 0
Study 33123802 — intervention group
Group type: COMPARATOR
Intervention: Control (fasted state)
Number of subjects: 0
Study 36195692 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical Decision Support Tool (DST)
Number of subjects: 0
Study 36195692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Technical and Non-Technical DST
Number of subjects: 0
Study 36195692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Technical DST
Number of subjects: 0
Study 36195692 — intervention group
Group type: EXPERIMENTAL
Intervention: All DSTs
Number of subjects: 0
Study 36195692 — intervention group
Group type: COMPARATOR
Intervention: Memory alone
Number of subjects: 0
Study 33609343 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Physical Therapy (PPT)
Number of subjects: 35
Study 33609343 — intervention group
Group type: COMPARATOR
Intervention: Maintenance Physical Therapy (MPT)
Number of subjects: 35
Study 32910735 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sEMG patch
Number of subjects: 40
Study 36048440 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent management training program including time-out; 10 sessions, social learning-based.
Number of subjects: 205
Study 36048440 — intervention group
Group type: COMPARATOR
Intervention: Control condition (waiting list).
Number of subjects: 205
Study 33662017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) plus meibomian gland expression (MGX)
Number of subjects: 60
Study 33662017 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) alone
Number of subjects: 60
Study 33440441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpancreatic biliary sphincterotomy (TPBS)
Number of subjects: 203
Study 33440441 — intervention group
Group type: COMPARATOR
Intervention: Double guidewire (DGW)
Number of subjects: 203
Study 35270295 — intervention group
Group type: EXPERIMENTAL
Intervention: Long HIIE (2 min at 100% vVO2peak + 2 min of passive rest)
Number of subjects: 44
Study 35270295 — intervention group
Group type: EXPERIMENTAL
Intervention: Short HIIE (30 s at 100% vVO2peak + 30 s of passive rest)
Number of subjects: 44
Study 35270295 — intervention group
Group type: COMPARATOR
Intervention: MICE (14 min at 70% vVO2peak)
Number of subjects: 44
Study 35486228 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (group 1)
Number of subjects: 63
Study 35486228 — intervention group
Group type: COMPARATOR
Intervention: 5‐Fu and leucovorin (group 2)
Number of subjects: 63
Study 33845988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-enriched transfer medium (EmbryoGlue, 0.5 mg/mL)
Number of subjects: 550
Study 33845988 — intervention group
Group type: COMPARATOR
Intervention: Standard transfer medium (supplemented G-2, 0.125 mg/mL)
Number of subjects: 550
Study 35589874 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAPS (closed-loop automated blood pressure control system)
Number of subjects: 40
Study 35589874 — intervention group
Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 40
Study 35589874 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAPS
Number of subjects: 40
Study 35589874 — intervention group
Group type: COMPARATOR
Intervention: CLAPS and Manual
Number of subjects: 40
Study 33789642 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate telemedicine linkage to the provider and transportation to pick up induction prescription or attend intake appointment.
Number of subjects: 273
Study 33789642 — intervention group
Group type: COMPARATOR
Intervention: Standard referral to treatment.
Number of subjects: 273
Study 33789642 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate telemedicine linkage to the provider.
Number of subjects: 273
Study 35073909 — intervention group
Group type: EXPERIMENTAL
Intervention: sQ-HPF questionnaire
Number of subjects: 4400
Study 35996823 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Contacts (3 communications via email or mail on days 4, 21, and 56 post-discharge)
Number of subjects: 100
Study 35996823 — intervention group
Group type: COMPARATOR
Intervention: Control communication (3 communications via email or mail on days 4, 21, and 56 post-discharge)
Number of subjects: 100
Study 33478976 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimen (40 mg/m2 on alternate days for 2 weeks)
Number of subjects: 117
Study 33478976 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (40 mg/m2 on alternate days for 4 weeks)
Number of subjects: 117
Study 33478976 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimen
Number of subjects: 117
Study 33478976 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 117
Study 33478976 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimen and Standard regimen
Number of subjects: 117
Study 33283533 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative breathing training
Number of subjects: 240
Study 33283533 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard perioperative care)
Number of subjects: 240
Study 34469484 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 241
Study 34469484 — intervention group
Group type: COMPARATOR
Intervention: Didactic teaching
Number of subjects: 241
Study 34469484 — intervention group
Group type: COMPARATOR
Intervention: Web-based e-learning
Number of subjects: 241
Study 36343085 — intervention group
Group type: EXPERIMENTAL
Intervention: Healbot T with pelvic off mode (pelvic off group; n = 11)
Number of subjects: 47
Study 36343085 — intervention group
Group type: EXPERIMENTAL
Intervention: Healbot T with pelvic control mode (pelvic on group; n = 12)
Number of subjects: 47
Study 36343085 — intervention group
Group type: EXPERIMENTAL
Intervention: Healbot T with constraint-induced movement therapy (CIMT) mode (CIMT group; n = 10)
Number of subjects: 47
Study 36343085 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group; n = 10)
Number of subjects: 47
Study 33156725 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant-led sessions on a thoracoscopic simulator
Number of subjects: 32
Study 33156725 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning sessions on a thoracoscopic simulator
Number of subjects: 32
Study 33156725 — intervention group
Group type: COMPARATOR
Intervention: Self-directed 'virtual training' on the 'SimuSurg' application
Number of subjects: 32
Study 33156725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 33156725 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study 35119520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Flex™ and daily text messages for 12 weeks
Number of subjects: 42
Study 35119520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 33877855 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB-navigated ND
Number of subjects: 271
Study 33877855 — intervention group
Group type: COMPARATOR
Intervention: Elective neck dissection (ND)
Number of subjects: 271
Study 33740213 — intervention group
Group type: EXPERIMENTAL
Intervention: Epic Allies mobile app intervention
Number of subjects: 146
Study 33740213 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 146
Study 32355108 — intervention group
Group type: EXPERIMENTAL
Intervention: Extragenital screening at both sites (rectal and pharyngeal)
Number of subjects: 0
Study 32355108 — intervention group
Group type: EXPERIMENTAL
Intervention: Extragenital screening only at the rectal site
Number of subjects: 0
Study 32355108 — intervention group
Group type: EXPERIMENTAL
Intervention: Extragenital screening only at the pharyngeal site
Number of subjects: 0
Study 32355108 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing only rectal screening
Number of subjects: 0
Study 35649245 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR443060 (DNL747)
Number of subjects: 0
Study 33682378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (continued treatment every 2 weeks)
Number of subjects: 158
Study 33682378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal of ixekizumab treatment every 2 weeks)
Number of subjects: 158
Study 33682378 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with ixekizumab after relapse
Number of subjects: 158
Study 35282441 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg) three times a day plus phentermine hydrochloride (37.5 mg) once daily
Number of subjects: 51
Study 35282441 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day plus phentermine hydrochloride (37.5 mg) once daily
Number of subjects: 51
Study 35432817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve block anesthesia
Number of subjects: 128
Study 35432817 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 128
Study 33287300 — intervention group
Group type: EXPERIMENTAL
Intervention: Donkey milk fortifier
Number of subjects: 122
Study 33287300 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived fortifier
Number of subjects: 122
Study 36213959 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care with community and primary healthcare workers' support
Number of subjects: 240
Study 36213959 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic-based care
Number of subjects: 240
Study 34751777 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPCAR levels
Number of subjects: 967
Study 34751777 — intervention group
Group type: EXPERIMENTAL
Intervention: High LIPCAR levels
Number of subjects: 967
Study 36375977 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate (0.4 mg orally per day)
Number of subjects: 128
Study 36375977 — intervention group
Group type: COMPARATOR
Intervention: omega-3 fatty acid ethyl esters (4 g orally per day)
Number of subjects: 128
Study 32639244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet for 8 weeks
Number of subjects: 100
Study 32639244 — intervention group
Group type: COMPARATOR
Intervention: AHA-recommended diet for 8 weeks
Number of subjects: 100
Study 35490744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg daily for 28 days, then 20 mg BID for 56 days
Number of subjects: 22
Study 34494076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention education program (1-day face-to-face workshop)
Number of subjects: 200
Study 33346856 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient concerns inventory (PCI) intervention used in outpatient clinics for one year after treatment.
Number of subjects: 288
Study 33346856 — intervention group
Group type: COMPARATOR
Intervention: Control group (not using PCI).
Number of subjects: 288
Study 33346856 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient concerns inventory (PCI) intervention.
Number of subjects: 288
Study 33066800 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Retrieval Practitioners (non-physicians) using ultrasound to diagnose pneumothorax
Number of subjects: 12
Study 33066800 — intervention group
Group type: COMPARATOR
Intervention: Expert review of ultrasound images
Number of subjects: 12
Study 34495879 — intervention group
Group type: COMPARATOR
Intervention: Low-income children
Number of subjects: 958
Study 34495879 — intervention group
Group type: COMPARATOR
Intervention: Low-income children (< 2 years old)
Number of subjects: 958
Study 34495879 — intervention group
Group type: COMPARATOR
Intervention: Older children
Number of subjects: 958
Study 32307012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg NaHCO3 solution
Number of subjects: 10
Study 32307012 — intervention group
Group type: COMPARATOR
Intervention: Water as a placebo
Number of subjects: 10
Study 33884909 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium trials (details on dosage and duration not available)
Number of subjects: 0
Study 32548759 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 Y-STR loci analysis
Number of subjects: 310
Study 34042297 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting by bike (BIKE, n=14)
Number of subjects: 72
Study 34042297 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of moderate intensity (MOD, n=28)
Number of subjects: 72
Study 34042297 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of vigorous intensity (VIG, n=18)
Number of subjects: 72
Study 34042297 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=12)
Number of subjects: 72
Study 33085578 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation e‐visit
Number of subjects: 51
Study 33085578 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study 36531558 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone 50 mg daily for three months
Number of subjects: 100
Study 36531558 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for three months
Number of subjects: 100
Study 36531558 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone 50 mg daily
Number of subjects: 100
Study 36531558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33082191 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 5 mg/kg/day
Number of subjects: 0
Study 33082191 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 10 mg/kg/day
Number of subjects: 0
Study 33082191 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 15 mg/kg/day
Number of subjects: 0
Study 33082191 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg/day
Number of subjects: 0
Study 33082191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35914543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 636
Study 35914543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 636
Study 35914543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 636